AstraZeneca (LON:AZN) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

AstraZeneca PLC (LON:AZN)’s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of £112.23 ($147.05) and traded as high as £115.52 ($151.36). AstraZeneca shares last traded at £113.92 ($149.27), with a volume of 1,971,750 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AZN shares. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Friday, March 7th. Finally, Berenberg Bank reissued a “buy” rating and issued a GBX 140 ($1.83) target price on shares of AstraZeneca in a research note on Wednesday, March 26th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($98.83).

AstraZeneca Trading Up 1.5 %

The firm has a market capitalization of £219.19 billion, a P/E ratio of 31.23, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The stock’s 50-day simple moving average is £116.11 and its two-hundred day simple moving average is £112.23.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.